Guido Marcucci, MD
Enriched profileProfessor, Department of Hematology and Hematopoietic Cell Transplantation; Founding Chair, Department of Hematologic Malignancies Translational Science; Founding Chief, Division of Leukemia; Founding Director, Gehr Family Center for Leukemia Research · City of Hope Comprehensive Cancer Center
Guido Marcucci is Professor, Department of Hematology and Hematopoietic Cell Transplantation; Founding Chair, Department of Hematologic Malignancies Translational Science; Founding Chief, Division of Leukemia; Founding Director, Gehr Family Center for Leukemia Research at City of Hope Comprehensive Cancer Center. OpenAlex indexes 1,183 publications with 54,499 citations (h-index 118); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Guido Marcucci, MD, is Professor, Department of Hematology and Hematopoietic Cell Transplantation at City of Hope Comprehensive Cancer Center, Duarte, CA. The public record shows 1,183 publications with 54,499 citations (h-index 118), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 11 companies, 8 NIH-funded awards (2015–2026).
- Most recent indexed publication: 2026 · Cancer research
- Top research focus: Acute Myeloid Leukemia Research
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 43 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 452.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
Sponsor: City of Hope Medical Center
- Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Sponsor: Skyline Diagnostics BV
Industry payments
Updated 14 Oct 2026
11 companies reported payments to CMS in program years 2021–2023. These are public disclosures, not judgments. The latest:
- Astellas Pharma Global DevelopmentProgram year20231 payment$25,000openpaymentsdata.cms.gov ↗
- SERVIER PHARMACEUTICALS LLCProgram year20238 payments
- Rigel Pharmaceuticals, Inc.Program year20238 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Jakafi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
8 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- State-transition and leukemia potential dynamics to inform disease evolution and adaptive therapy
Beckman Research Institute/city of Hope
FY2026$590,960U01CA293853 - Targeting Immune Escape in CML/MPN Transformation
Beckman Research Institute/city of Hope
FY2026$571,615R01CA286160 - The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
Beckman Research Institute/city of Hope
FY2026$542,890R01CA258981
Congress activity
Updated 14 Oct 2026
240 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Abstract 14: Molecular drivers of lineage bias in TP53-mutant therapy-related acute leukemias
AACR Annual Meeting
AACR2025Co-author - Abstract 4843: TET2 oxidizes chromatin-associated regulatory RNA m5C to potentiate anti-tumor immunity
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Targeting microRNAs in cancer: rationale, strategies and challenges1,494 citations2010
- 04Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia1,378 citations2014
- 05R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling1,193 citations2017
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/guido-marcucci-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/guidomarcucci
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Google Scholar
scholar.google.com/citations
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Guido-Marcucci-40023623
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Catholic University of the Sacred Heart, Rome, Italy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ostentus.mobirisesite.com ↗ - Residency
Internal Medicine, State University of New York at Buffalo
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ostentus.mobirisesite.com ↗ - Fellowship
Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ostentus.mobirisesite.com ↗ - Board Certified
Internal Medicine and Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.com ↗
Editorial & leadership roles
journal and society appointments- Founding Chair
Department of Hematologic Malignancies Translational Science, City of Hope
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Founding Chief
Division of Leukemia, City of Hope
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Founding Director
Gehr Family Center for Leukemia Research, City of Hope
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Director
City of Hope Hematopoietic Tissue Biorepository
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ostentus.mobirisesite.com ↗
Awards & honors
honors on the public record- Elected Member
Association of American Physicians (AAP)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ostentus.mobirisesite.com ↗ - V Foundation for Cancer Research Translational Grant recipient
"Immunotherapeutic targeting of IL-1-RAP to eliminate leukemia stem cells (LSC) in Acute Myeloid Leukemia (AML)"
- Charles A. Doan Chair of Medicine
Ohio State University (named chair, prior institution)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ostentus.mobirisesite.com ↗
Secondary affiliations
appointments beyond the home institution- Formerly Professor of Internal Medicine
Molecular Virology/Immunology/Medical Genetics, and Pharmaceutics (Division of Hematology), The Ohio State University Comprehensive Cancer Center, until 2014/2015
2015verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - MD Advisor
Ostentus Therapeutics Inc.
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ostentus.mobirisesite.com ↗
Media & interviews
press, podcasts and appearances- "Internationally Acclaimed Hematologist-Oncologist Guido Marcucci, M.D., Joins City of Hope"
Business Wire press release, Jan 26
2015verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →businesswire.com ↗ - "Physician-Scientist Guido Marcucci, MD, Joins City of Hope"
profile feature, The ASCO Post, Feb 25
2015verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Stephen Forman, MD
City of Hope Comprehensive Cancer Center
Marwan Fakih, MD
City of Hope Comprehensive Cancer Center
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center